{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:58:57Z","timestamp":1789225137251,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jfma.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:37:33Z","timestamp":1709199453000},"page":"891-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy"],"prefix":"10.1016","volume":"123","author":[{"given":"Kai-Chun","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-2768","authenticated-orcid":false,"given":"Sih-Han","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-9627","authenticated-orcid":false,"given":"Shang-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.02.011_bib1","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact: web annex 2: data methods","author":"World Health","year":"2021"},{"key":"10.1016\/j.jfma.2024.02.011_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.jfma.2024.02.011_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2024.02.011_bib4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2024.02.011_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2024.02.011_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jfma.2024.02.011_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2024.02.011_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70433-z","article-title":"Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate","volume":"10","author":"Ha","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2024.02.011_bib9","first-page":"3882","article-title":"Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study","volume":"10","author":"Chen","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jfma.2024.02.011_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2024.02.011_bib11","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2024.02.011_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2024.02.011_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejim.2021.02.019","article-title":"The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma","volume":"89","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jfma.2024.02.011_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000518940","article-title":"Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0\/A hepatocellular carcinoma after curative resection","volume":"11","author":"Tsai","year":"2022","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.jfma.2024.02.011_bib15","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jfma.2021.12.024","article-title":"Quality assurance of integrative big data for medical research within a multihospital system","volume":"121","author":"Lee","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.02.011_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2024.02.011_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.jfma.2024.02.011_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jfma.2024.02.011_bib19","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.jfma.2024.02.011_bib20","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jfma.2024.02.011_bib21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jfma.2020.11.019","article-title":"Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy","volume":"120","author":"Wu","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.02.011_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12876-020-01235-w","article-title":"Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jfma.2024.02.011_bib23","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/liv.15052","article-title":"Paradigm shift in the treatment options of hepatocellular carcinoma","volume":"42","author":"Su","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2024.02.011_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/bjc.2013.352","article-title":"Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma","volume":"109","author":"Wang","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2024.02.011_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00423-010-0643-0","article-title":"Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver","volume":"395","author":"Abdel-Wahab","year":"2010","journal-title":"Langenbeck's Arch Surg"},{"key":"10.1016\/j.jfma.2024.02.011_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-018-19251-y","article-title":"Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation","volume":"8","author":"Ho","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2024.02.011_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2020.05.003","article-title":"Tenofovir is superior to entecavir in patients with treatment-na\u00efve hepatitis B e-antigen-positive chronic hepatitis B","volume":"11","author":"Behera","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jfma.2024.02.011_bib28","article-title":"Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery","volume":"10","author":"Cho","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2024.02.011_bib29","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.06.01","article-title":"Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy","volume":"7","author":"Ye","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jfma.2024.02.011_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2024.02.011_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/v13061090","article-title":"Review of lambda interferons in hepatitis B virus infection: outcomes and therapeutic strategies","volume":"13","author":"Novotny","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2024.02.011_bib32","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jfma.2024.02.011_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.hepres.2003.07.002","article-title":"Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma","volume":"27","author":"Hattori","year":"2003","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2024.02.011_bib34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T01:02:31Z","timestamp":1729213351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0929664624001116"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.02.011","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}